For: | Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report. World J Hepatol 2016; 8(20): 858-862 [PMID: 27458506 DOI: 10.4254/wjh.v8.i20.858] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v8/i20/858.htm |
Number | Citing Articles |
1 |
Mayadah M. Abdelsalam, Nageh El-Mahdy, Sabry Abou-Saif. Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice. Liver Research 2023; 7(1): 71 doi: 10.1016/j.livres.2023.02.001
|
2 |
Ohad Etzion, Harel Dahari, David Yardeni, Assaf Issachar, Anat Nevo-Shor, Michal Cohen-Naftaly, Yaffa Ashur, Susan L. Uprichard, Orly Sneh Arbib, Daniela Munteanu, Marius Braun, Scott J. Cotler, Naim Abufreha, Ayelet Keren-Naus, Yonat Shemer-Avni, Orna Mor, Jayanah Murad, Victor Novack, Amir Shlomai. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-74568-x
|
3 |
Ashish Goyal, Yoav Lurie, Eric G. Meissner, Marian Major, Natasha Sansone, Susan L. Uprichard, Scott J. Cotler, Harel Dahari. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Research 2017; 144: 281 doi: 10.1016/j.antiviral.2017.06.019
|
4 |
Crina Fofiu, Alina Boeriu, Felicia Coman, Alexandru Fofiu, Nikola Panic, Milutin Bulajic, Daniela Dobru. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Annals of Hepatology 2019; 18(1): 137 doi: 10.5604/01.3001.0012.7905
|
5 |
Rosa Zampino, Martina Vitrone, Antonio Parrella, Enrico Ragone, Emanuele Durante-Mangoni. Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases. Journal of Chemotherapy 2018; 30(2): 129 doi: 10.1080/1120009X.2017.1376782
|
6 |
Subhasish Baral, Rahul Roy, Narendra M Dixit. Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct‐acting antiviral agents. Immunology & Cell Biology 2018; 96(9): 969 doi: 10.1111/imcb.12161
|
7 |
Vinicius Lins Ferreira, Leticia Paula Leonart, Ana Maria Della Rocca, Roberto Pontarolo. Analysis of Safety Outcomes in Chronic Hepatitis C Patients using Interferon-free Treatment: A Systematic Review of Case Reports. Current Drug Therapy 2019; 14(3): 210 doi: 10.2174/1574885514666190130162547
|
8 |
Omar Shahbaz, Sandeep Mahajan, James H. Lewis. Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?. Expert Opinion on Drug Metabolism & Toxicology 2017; 13(9): 935 doi: 10.1080/17425255.2017.1362391
|
9 |
Rubesh Raja, Subhasish Baral, Narendra M. Dixit. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era. Immunological Reviews 2018; 285(1): 55 doi: 10.1111/imr.12689
|